San Francisco, CA, United States of America

Mark Michael Menning

This inventor holds 14 USPTO granted patents and 11 published patent applications, plus 3 CIPO patents and 5 EPO patents, primarily in Pharmaceutical Formulations. Top assignees: Gilead Sciences, Inc., Bristol-Myers Squibb & Gilead Sciences, Inc., Eidos Therapeutics, Inc.. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mark Michael Menning. Retrieved from https://idiyas.com/inventor/mark-michael-menning

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 14 (Patent Applications = 11)

% Patents Active = 71.4

CIPO Patents = 3 (Patent Applications = 5)

EPO Patents = 5 (Patent Applications = 11)

Average Co-Inventor Count = 3.1

ph-index = 6

Forward Citations = 126(Granted Patents)

Location History:

Foster City, CA (US) (2018)
San Francisco, CA (US) (2013 - 2024)

Company Filing History:

7 out of 946

Gilead Sciences, Inc.

patents

3 out of 3

Bristol-Myers Squibb & Gilead Sciences, Inc.

patents

3 out of 8

Eidos Therapeutics, Inc.

patents

4. 1 out of 111

Janssen Sciences Ireland Uc

patents

5. 1 out of 8

Tobira Therapeutics, Inc.

patents

where one patent can have more than one assignee

Years Active: 2013-2026

Loading Chart...

Areas of Expertise:

AG10

Rilpivirine HCL

Tenofovir Disoproxil Fumarate

Solid Carrier Particles

Antiviral Therapy

Lamivudine Salts

Pharmaceutical Dosage Form

Combination Therapy

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12539290 - Formulations of AG10 (2026-02-03),

2. 12005043 - Formulations of AG10 (2024-06-11),

3. 11260047 - Formulations of AG10 (2022-03-01),

4. 10857102 - Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate (2020-12-08),

5. 10039718 - Use of solid carrier particles to improve the processability of a pharmaceutical agent (2018-08-07),

6. 9744181 - Compositions and methods for combination antiviral therapy (2017-08-29),

7. 9688666 - Lamivudine salts (2017-06-27),

8. 9545414 - Unitary pharmaceutical dosage form (2017-01-17),

9. 9457036 - Compositions and methods for combination antiviral therapy (2016-10-04),

10. 9018192 - Unitary pharmaceutical dosage form (2015-04-28),

11. 8871271 - Method and composition for pharmaceutical product (2014-10-28),

12. 8716264 - Compositions and methods for combination antiviral therapy (2014-05-06),

13. 8598185 - Unitary pharmaceutical dosage form (2013-12-03),

14. 8592397 - Compositions and methods for combination antiviral therapy (2013-11-26),

Title: Unveiling the Innovative Mind of Mark Michael Menning

Introduction:

Mark Michael Menning is a prolific inventor based in San Francisco, CA, known for his significant contributions to the field of pharmaceutical formulations. With an impressive portfolio of 13 patents, Menning's work reflects a dedication to advancing the healthcare industry through innovation.

Latest Patents:

Menning's latest patents showcase his expertise in developing high-load tablet formulations of AG10, a promising pharmaceutical compound. These formulations include a high percentage of AG10 by weight, along with various pharmaceutical excipients such as fillers, binders, disintegrants, and lubricants.

Career Highlights:

Menning has made his mark in renowned companies such as Gilead Sciences, Inc. and Bristol-Myers Squibb. His tenure in these organizations demonstrates his ability to thrive in dynamic and cutting-edge work environments, where his innovative ideas have flourished.

Collaborations:

Throughout his career, Menning has collaborated with esteemed professionals in the industry, including Reza Oliyai and Terrence C. Dahl. These collaborations have not only enhanced Menning's own work but have also led to valuable advancements in pharmaceutical research and development.

Conclusion:

In conclusion, Mark Michael Menning stands as a visionary inventor whose dedication to creating novel pharmaceutical formulations has garnered recognition in the industry. His patents and collaborations underscore his commitment to pushing the boundaries of innovation, making him a key figure in shaping the future of healthcare technologies.

Profile summary based on public USPTO records.